Organisation paid for research Program year 2024 Source: CMS Open Payments

Cedar-Crosse Research Center

Neither a doctor nor a teaching hospital

Research payments

$407,772

31 payments

Through program year 2024, Cedar-Crosse Research Center is reported as receiving $407,772 in research payments, across 31 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $6,794 1
2023 Research $278,461 12
2021 Research $2,486 3
2020 Research $118,331 13
2019 Research $1,700 2

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novavax Inc $285,255 13 payments
  2. H. Lundbeck A S $120,817 16 payments
  3. Teva Pharmaceuticals USA, Inc. $1,700 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) $278,461 12 payments
  2. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $60,621 3 payments
  3. A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing An Acute Attack of Migraine $60,196 13 payments
  4. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years with a Pediatric Expansion in Adolescents (12 to younger than 18 Years) $6,794 1 payment
  5. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments $1,700 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record